ID

30354

Descrizione

Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00446095

collegamento

https://clinicaltrials.gov/show/NCT00446095

Keywords

versioni (1)
  1. 29/05/18 29/05/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

29 maggio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Lymphoma NCT00446095

Inglese

Eligibility Lymphoma NCT00446095

1 moduli  
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00446095
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients must be > 18 years old.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
2. patients must be willing and able to give written informed consent by signing an irb-approved informed consent form prior to admission to this study and must fully understand the requirements of the study and be willing to comply with all study visits and assessments.
Descrizione

Informed Consent | Protocol Compliance

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
3. patients with relapsed/refractory b-cell malignancy, (dlbcl, follicular lymphoma, mantle cell lymphoma, malt lymphoma, marginal zone lymphoma, cll or sll), who have failed at least one prior treatment regimen and for whom no standard therapy exists; patients who are intolerant of standard therapy or who are not candidates for available standard therapy may also be included.
Descrizione

B-cell Malignant Neoplasms Recurrent | B-cell Malignant Neoplasms Refractory | Diffuse Large B-Cell Lymphoma | Lymphoma, Follicular | Mantle cell lymphoma | MALT Lymphoma | Marginal Zone B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Prior Therapy Quantity failed | Standard of Care Absent | Intolerance Standard of Care | Patients Inappropriate Standard of Care

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0004561
UMLS CUI [1,2]
C0006826
UMLS CUI [1,3]
C0277556
UMLS CUI [2,1]
C0004561
UMLS CUI [2,2]
C0006826
UMLS CUI [2,3]
C0205269
UMLS CUI [3]
C0079744
UMLS CUI [4]
C0024301
UMLS CUI [5]
C0334634
UMLS CUI [6]
C0242647
UMLS CUI [7]
C1367654
UMLS CUI [8]
C0023434
UMLS CUI [9]
C0855095
UMLS CUI [10,1]
C1514463
UMLS CUI [10,2]
C1265611
UMLS CUI [10,3]
C0231175
UMLS CUI [11,1]
C2936643
UMLS CUI [11,2]
C0332197
UMLS CUI [12,1]
C0231199
UMLS CUI [12,2]
C2936643
UMLS CUI [13,1]
C0030705
UMLS CUI [13,2]
C1548788
UMLS CUI [13,3]
C2936643
4. patients must have measurable disease.
Descrizione

Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
5. patients may be male or female. men, if sexually active, must agree to use at least one medically acceptable form of birth control for the duration of the study and for 30 days thereafter. sexually active women of childbearing potential must have a negative serum pregnancy test, and agree to use two independent methods of birth control for the duration of the study and for 30 days thereafter.
Descrizione

Gender Sexually active Contraceptive methods Quantity | Childbearing Potential Sexually active Serum pregnancy test negative | Childbearing Potential Sexually active Contraceptive methods Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0241028
UMLS CUI [1,3]
C0700589
UMLS CUI [1,4]
C1265611
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0241028
UMLS CUI [2,3]
C0430061
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0241028
UMLS CUI [3,3]
C0700589
UMLS CUI [3,4]
C1265611
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients with t-cell lymphoma or primary cns lymphoma
Descrizione

T-Cell Lymphoma | Primary central nervous system lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079772
UMLS CUI [2]
C0280803
2. patients with a history of malignancy other than lymphoma, except basal cell carcinoma of the skin and in situ cervical carcinoma, if < 2 years since curative treatment
Descrizione

Cancer Other | Exception Lymphoma | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Carcinoma in situ of uterine cervix

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0024299
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0007117
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1273390
UMLS CUI [4,3]
C0851140
3. chemotherapy within 4 weeks of day 1 of treatment (6 weeks for mitomycin c and nitrosoureas)
Descrizione

Chemotherapy | Mitomycin | Nitrosourea

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0002475
UMLS CUI [3]
C0028210
4. antibody therapy or lymphoma vaccine therapy within 6 weeks of day 1
Descrizione

Antibody therapy | Lymphoma Vaccine Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0281176
UMLS CUI [2,1]
C0024299
UMLS CUI [2,2]
C0042209
5. radiotherapy within 2 weeks of day 1, 4 weeks if to marrow-bearing sites (sternum, pelvis)
Descrizione

Therapeutic radiology procedure Bone Marrow Site | Therapeutic radiology procedure Sternum | Radiotherapy to pelvis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C1515974
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0038293
UMLS CUI [3]
C1536155
6. any other investigational therapy within 4 weeks of day 1
Descrizione

Therapies, Investigational

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0949266
7. significant gastrointestinal disease (crohn's or ulcerative colitis) or major gastric or small bowel surgery
Descrizione

Gastrointestinal Disease | Crohn Disease | Ulcerative Colitis | Operation on stomach Major | Operative procedure on small intestine Major

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0017178
UMLS CUI [2]
C0010346
UMLS CUI [3]
C0009324
UMLS CUI [4,1]
C0192398
UMLS CUI [4,2]
C0205164
UMLS CUI [5,1]
C0192571
UMLS CUI [5,2]
C0205164
8. difficulty swallowing or malabsorption
Descrizione

Swallowing problem | Malabsorption

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0392678
UMLS CUI [2]
C3714745
9. patients with bone marrow impairment: hgb < 9.0 g/dl; anc < 1500/μl; platelets < 75,000/μl
Descrizione

Bone Marrow Impaired | Hemoglobin measurement | Absolute neutrophil count | Platelet Count measurement

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0221099
UMLS CUI [2]
C0518015
UMLS CUI [3]
C0948762
UMLS CUI [4]
C0032181
10. patients with impairment of renal function: creatinine > 2.0 g/dl
Descrizione

Renal Insufficiency | Creatinine measurement, serum

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
11. patients with abnormal liver function: ast/alt > 3x uln (up to 5x uln with liver involvement); bilirubin > 1.5 mg/dl
Descrizione

Liver Dysfunction | Aspartate aminotransferase increased | Alanine aminotransferase increased | Liver Involvement | Serum total bilirubin measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0086565
UMLS CUI [2]
C0151904
UMLS CUI [3]
C0151905
UMLS CUI [4,1]
C0023884
UMLS CUI [4,2]
C1314939
UMLS CUI [5]
C1278039
12. patients who have been treated with a cyp3a4 inducer/inhibitor within 1 week prior to day 1 or who are expected to require treatment with cyp3a4 inducer/inhibitor during the course of the study (appendix iv)
Descrizione

CYP3A4 Inducer | CYP3A4 Inhibitor | CYP3A4 Inducer Expected | CYP3A4 Inhibitor Expected

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3830625
UMLS CUI [2]
C3830624
UMLS CUI [3,1]
C3830625
UMLS CUI [3,2]
C1517001
UMLS CUI [4,1]
C3830624
UMLS CUI [4,2]
C1517001
13. patients with karnofsky performance status < 60% (appendix i)
Descrizione

Karnofsky Performance Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206065
14. patients whose life expectancy is < 3 months
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
15. patients who are known to be hiv positive
Descrizione

HIV Seropositivity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019699
16. patients who have a history of any other significant medical or physical condition that might impair the patient's well being or preclude full participation in the study
Descrizione

Medical condition Impairing Patient Health | Physical Condition Impairing Patient Health | Medical condition Study Subject Participation Status Limited | Physical Condition Study Subject Participation Status Limited

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0221099
UMLS CUI [1,3]
C0030705
UMLS CUI [1,4]
C0018684
UMLS CUI [2,1]
C3714565
UMLS CUI [2,2]
C0221099
UMLS CUI [2,3]
C0030705
UMLS CUI [2,4]
C0018684
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C0439801
UMLS CUI [4,1]
C3714565
UMLS CUI [4,2]
C2348568
UMLS CUI [4,3]
C0439801
17. pregnant or nursing females
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
18. patients receiving systemic or chronic inhaled steroids, with the exception of intermittent dexamethasone for the treatment of emesis or intermittent steroid inhalers for exacerbations of asthma
Descrizione

Inhaled steroids Systemic | Inhaled steroids chronic | Exception Dexamethasone Vomiting | Exception Steroid Inhaler Exacerbation of asthma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2065041
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C2065041
UMLS CUI [2,2]
C0205191
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0011777
UMLS CUI [3,3]
C0042963
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0038317
UMLS CUI [4,3]
C0021461
UMLS CUI [4,4]
C0349790
Ritorna all'inizio della pagina

Similar models

Eligibility Lymphoma NCT00446095

1 moduli
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00446095
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. patients must be > 18 years old.
boolean
C0001779 (UMLS CUI [1])
Informed Consent | Protocol Compliance
Item
2. patients must be willing and able to give written informed consent by signing an irb-approved informed consent form prior to admission to this study and must fully understand the requirements of the study and be willing to comply with all study visits and assessments.
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
B-cell Malignant Neoplasms Recurrent | B-cell Malignant Neoplasms Refractory | Diffuse Large B-Cell Lymphoma | Lymphoma, Follicular | Mantle cell lymphoma | MALT Lymphoma | Marginal Zone B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Prior Therapy Quantity failed | Standard of Care Absent | Intolerance Standard of Care | Patients Inappropriate Standard of Care
Item
3. patients with relapsed/refractory b-cell malignancy, (dlbcl, follicular lymphoma, mantle cell lymphoma, malt lymphoma, marginal zone lymphoma, cll or sll), who have failed at least one prior treatment regimen and for whom no standard therapy exists; patients who are intolerant of standard therapy or who are not candidates for available standard therapy may also be included.
boolean
C0004561 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0277556 (UMLS CUI [1,3])
C0004561 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0079744 (UMLS CUI [3])
C0024301 (UMLS CUI [4])
C0334634 (UMLS CUI [5])
C0242647 (UMLS CUI [6])
C1367654 (UMLS CUI [7])
C0023434 (UMLS CUI [8])
C0855095 (UMLS CUI [9])
C1514463 (UMLS CUI [10,1])
C1265611 (UMLS CUI [10,2])
C0231175 (UMLS CUI [10,3])
C2936643 (UMLS CUI [11,1])
C0332197 (UMLS CUI [11,2])
C0231199 (UMLS CUI [12,1])
C2936643 (UMLS CUI [12,2])
C0030705 (UMLS CUI [13,1])
C1548788 (UMLS CUI [13,2])
C2936643 (UMLS CUI [13,3])
Measurable Disease
Item
4. patients must have measurable disease.
boolean
C1513041 (UMLS CUI [1])
Gender Sexually active Contraceptive methods Quantity | Childbearing Potential Sexually active Serum pregnancy test negative | Childbearing Potential Sexually active Contraceptive methods Quantity
Item
5. patients may be male or female. men, if sexually active, must agree to use at least one medically acceptable form of birth control for the duration of the study and for 30 days thereafter. sexually active women of childbearing potential must have a negative serum pregnancy test, and agree to use two independent methods of birth control for the duration of the study and for 30 days thereafter.
boolean
C0079399 (UMLS CUI [1,1])
C0241028 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
C3831118 (UMLS CUI [2,1])
C0241028 (UMLS CUI [2,2])
C0430061 (UMLS CUI [2,3])
C3831118 (UMLS CUI [3,1])
C0241028 (UMLS CUI [3,2])
C0700589 (UMLS CUI [3,3])
C1265611 (UMLS CUI [3,4])
Item Group
C0680251 (UMLS CUI)
T-Cell Lymphoma | Primary central nervous system lymphoma
Item
1. patients with t-cell lymphoma or primary cns lymphoma
boolean
C0079772 (UMLS CUI [1])
C0280803 (UMLS CUI [2])
Cancer Other | Exception Lymphoma | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Carcinoma in situ of uterine cervix
Item
2. patients with a history of malignancy other than lymphoma, except basal cell carcinoma of the skin and in situ cervical carcinoma, if < 2 years since curative treatment
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0024299 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0007117 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0851140 (UMLS CUI [4,3])
Chemotherapy | Mitomycin | Nitrosourea
Item
3. chemotherapy within 4 weeks of day 1 of treatment (6 weeks for mitomycin c and nitrosoureas)
boolean
C0392920 (UMLS CUI [1])
C0002475 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
Antibody therapy | Lymphoma Vaccine Therapy
Item
4. antibody therapy or lymphoma vaccine therapy within 6 weeks of day 1
boolean
C0281176 (UMLS CUI [1])
C0024299 (UMLS CUI [2,1])
C0042209 (UMLS CUI [2,2])
Therapeutic radiology procedure Bone Marrow Site | Therapeutic radiology procedure Sternum | Radiotherapy to pelvis
Item
5. radiotherapy within 2 weeks of day 1, 4 weeks if to marrow-bearing sites (sternum, pelvis)
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,3])
C1522449 (UMLS CUI [2,1])
C0038293 (UMLS CUI [2,2])
C1536155 (UMLS CUI [3])
Therapies, Investigational
Item
6. any other investigational therapy within 4 weeks of day 1
boolean
C0949266 (UMLS CUI [1])
Gastrointestinal Disease | Crohn Disease | Ulcerative Colitis | Operation on stomach Major | Operative procedure on small intestine Major
Item
7. significant gastrointestinal disease (crohn's or ulcerative colitis) or major gastric or small bowel surgery
boolean
C0017178 (UMLS CUI [1])
C0010346 (UMLS CUI [2])
C0009324 (UMLS CUI [3])
C0192398 (UMLS CUI [4,1])
C0205164 (UMLS CUI [4,2])
C0192571 (UMLS CUI [5,1])
C0205164 (UMLS CUI [5,2])
Swallowing problem | Malabsorption
Item
8. difficulty swallowing or malabsorption
boolean
C0392678 (UMLS CUI [1])
C3714745 (UMLS CUI [2])
Bone Marrow Impaired | Hemoglobin measurement | Absolute neutrophil count | Platelet Count measurement
Item
9. patients with bone marrow impairment: hgb < 9.0 g/dl; anc < 1500/μl; platelets < 75,000/μl
boolean
C0005953 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0518015 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
Renal Insufficiency | Creatinine measurement, serum
Item
10. patients with impairment of renal function: creatinine > 2.0 g/dl
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Liver Dysfunction | Aspartate aminotransferase increased | Alanine aminotransferase increased | Liver Involvement | Serum total bilirubin measurement
Item
11. patients with abnormal liver function: ast/alt > 3x uln (up to 5x uln with liver involvement); bilirubin > 1.5 mg/dl
boolean
C0086565 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
C0023884 (UMLS CUI [4,1])
C1314939 (UMLS CUI [4,2])
C1278039 (UMLS CUI [5])
CYP3A4 Inducer | CYP3A4 Inhibitor | CYP3A4 Inducer Expected | CYP3A4 Inhibitor Expected
Item
12. patients who have been treated with a cyp3a4 inducer/inhibitor within 1 week prior to day 1 or who are expected to require treatment with cyp3a4 inducer/inhibitor during the course of the study (appendix iv)
boolean
C3830625 (UMLS CUI [1])
C3830624 (UMLS CUI [2])
C3830625 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
C3830624 (UMLS CUI [4,1])
C1517001 (UMLS CUI [4,2])
Karnofsky Performance Status
Item
13. patients with karnofsky performance status < 60% (appendix i)
boolean
C0206065 (UMLS CUI [1])
Life Expectancy
Item
14. patients whose life expectancy is < 3 months
boolean
C0023671 (UMLS CUI [1])
HIV Seropositivity
Item
15. patients who are known to be hiv positive
boolean
C0019699 (UMLS CUI [1])
Medical condition Impairing Patient Health | Physical Condition Impairing Patient Health | Medical condition Study Subject Participation Status Limited | Physical Condition Study Subject Participation Status Limited
Item
16. patients who have a history of any other significant medical or physical condition that might impair the patient's well being or preclude full participation in the study
boolean
C3843040 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0018684 (UMLS CUI [1,4])
C3714565 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
C0018684 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C0439801 (UMLS CUI [3,3])
C3714565 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C0439801 (UMLS CUI [4,3])
Pregnancy | Breast Feeding
Item
17. pregnant or nursing females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Inhaled steroids Systemic | Inhaled steroids chronic | Exception Dexamethasone Vomiting | Exception Steroid Inhaler Exacerbation of asthma
Item
18. patients receiving systemic or chronic inhaled steroids, with the exception of intermittent dexamethasone for the treatment of emesis or intermittent steroid inhalers for exacerbations of asthma
boolean
C2065041 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C2065041 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0011777 (UMLS CUI [3,2])
C0042963 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0038317 (UMLS CUI [4,2])
C0021461 (UMLS CUI [4,3])
C0349790 (UMLS CUI [4,4])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial